Sponsor: Amgen, Inc.
Sponsor Study ID: 20200041
Study Title: A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination with Durvalumab compared With Durvalumab as Maintenance Therapy in Subjects with Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy with Platinum, Etoposide and Durvalumab
CTO #: 103967
NCT Number: NCT06211036
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung
Study Objectives: To compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS)